Willow Biosciences IncOTCQB:CANSFView on Canadian Exchange
- LAST PRICE0.0573
- TODAY'S CHANGE (%)0.0009 (1.6823%)
- Bid / Lots0.0551/ 100
- Ask / Lots0.0583/ 480
- Open / Previous Close0.0551 / 0.0564
- Day Range
- 52 Week Range
- Volume1,100
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | CANSF |
|---|---|---|
| 09:32 ET | 1000 | 0.0551 |
| 10:49 ET | 100 | 0.057298 |
Nov 18, 2024
WILLOW ANNOUNCES NON-BROKERED PRIVATE PLACEMENT OFFERING TO RAISE UP TO $2.0 MILLION, from 7:00AM ET on Monday Nov 18, 2024 by Dow Jones
7:00AM ET on Monday Nov 18, 2024 by Dow Jones
Nov 12, 2024
Press Release: WILLOW BIOSCIENCES REPORTS THIRD QUARTER 2024 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE, from 7:00AM ET on Tuesday Nov 12, 2024 by Dow Jones
7:00AM ET on Tuesday Nov 12, 2024 by Dow JonesWILLOW BIOSCIENCES REPORTS THIRD QUARTER 2024 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE, from 7:00AM ET on Tuesday Nov 12, 2024 by Dow Jones
7:00AM ET on Tuesday Nov 12, 2024 by Dow JonesPress Release: WILLOW BIOSCIENCES REPORTS THIRD QUARTER 2024 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE, from 7:00AM ET on Tuesday Nov 12, 2024 by Dow Jones
7:00AM ET on Tuesday Nov 12, 2024 by Dow Jones
Nov 7, 2024
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Willow Biosciences Inc | 11.5M | --- | --- |
Company Information
Willow Biosciences Inc. is a Canada-based biotechnology company. The Company develops and produces precision fermented functional ingredients for the health and wellness, food and beverage and personal care markets. Its FutureGrown biotechnology platform allows production with sustainability at its core. Its commercial product, Cannabigerol CBG, which is a cannabinoid that has anti-microbial, anti-inflammatory, and antioxidant properties. It also offers BioOxi, a bio-oxidation technology platform. By leveraging BioOxi, commercial partners can revolutionize manufacturing of oxygenated and hydroxylated functional ingredients, such as steroids, polyphenols, oxyterpenes and certain other targeted ingredients produced from such methods. It is also developing BioOxi-based process for production of the generic active pharmaceutical ingredient (API), hydrocortisone, and its derivatives. Its other pipeline products include Ursodeoxycholic acid (UCAC), Astaxanthin, B-carotene and others.
Contact Information
- Headquarters
- 202, 1201 5th Street SWCALGARY, AB, Canada T2R 0Y6
- Phone
- 403-910-5140
- Fax
- 403-669-4848
Executives
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $11.5M |
|---|---|
Revenue (TTM) | $2.9M |
Shares Outstanding | 144.2M |
Willow Biosciences Inc does not pay a dividend. | |
Beta | 1.11 |
EPS | $-0.06 |
Book Value | $0.03 |
P/E Ratio | --- |
Price/Sales (TTM) | 4.0 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -251.83% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
